{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:30:47Z","timestamp":1792798247952,"version":"4.5.0"},"reference-count":15,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>To study the efficacy of anakinra versus disease-modifying antirheumatic drugs (DMARD) in refractory adult-onset Still\u2019s disease (AOSD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>In a 24-week study, 22 patients with AOSD taking prednisolone \u2265 10 mg\/day received anakinra (n = 12) or DMARD (n = 10). The primary endpoint was achievement of remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>At 8 and 24 weeks, 7\/12 and 6\/12 receiving anakinra and 5\/10 and 2\/10 receiving DMARD achieved remission. Anakinra induced greater improvement in physical health measured by Medical Outcomes Study Short-Form 36 (SF-36; p &lt; 0.011). During an open-label extension (OLE) of 28 weeks, 7\/14 patients taking anakinra and 2\/3 taking DMARD were in remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>\n                      Anakinra induced more beneficial responses than DMARD in patients with AOSD and was favored in the OLE phase. (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"ClinicalTrials.gov\" ext-link-type=\"uri\" xlink:type=\"simple\">ClinicalTrials.gov<\/jats:ext-link>\n                      Protocol Registration\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01033656\">NCT01033656<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.111549","type":"journal-article","created":{"date-parts":[[2012,8,2]],"date-time":"2012-08-02T01:29:34Z","timestamp":1343870974000},"page":"2008-2011","source":"Crossref","is-referenced-by-count":155,"title":["Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still\u2019s Disease. An Open, Randomized, Multicenter Study"],"prefix":"10.3899","volume":"39","author":[{"given":"DAN","family":"NORDSTR\u00d6M","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANN","family":"KNIGHT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"REIJO","family":"LUUKKAINEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RONALD","family":"van VOLLENHOVEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VAPPU","family":"RANTALAIHO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANNA","family":"KAJALAINEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOHAN G.","family":"BRUN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANNE","family":"PROVEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LOTTA","family":"LJUNG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HANNU","family":"KAUTIAINEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TOM","family":"PETTERSSON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2012,8,1]]},"reference":[{"key":"2018112909282087000_39.10.2008.1","first-page":"2422","article-title":"Serum cytokine profiles in patients with adult-onset Still\u2019s disease","volume":"30","author":"Choi","year":"2003","journal-title":"J Rheumatol"},{"key":"2018112909282087000_39.10.2008.2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050640"},{"key":"2018112909282087000_39.10.2008.3","first-page":"1088","article-title":"Treatment of fulminant adult Still\u2019s disease with intravenous pulse methylprednisolone therapy","volume":"18","author":"Khraishi","year":"1991","journal-title":"J Rheumatol"},{"key":"2018112909282087000_39.10.2008.4","doi-asserted-by":"publisher","DOI":"10.1080\/030097400447624"},{"key":"2018112909282087000_39.10.2008.5","first-page":"1391","article-title":"Cyclosporin A in the treatment of adult Still\u2019s disease","volume":"22","author":"Shojania","year":"1995","journal-title":"J Rheumatol"},{"key":"2018112909282087000_39.10.2008.6","first-page":"431","article-title":"Low dose methotrexate treatment in adult onset Still\u2019s disease","volume":"19","author":"Aydintung","year":"1992","journal-title":"J Rheumatol"},{"key":"2018112909282087000_39.10.2008.7","first-page":"373","article-title":"Corticosteroid sparing effect of low dose methotrexate treatment in adult Still\u2019s disease","volume":"26","author":"Fautrel","year":"1999","journal-title":"J Rheumatol"},{"key":"2018112909282087000_39.10.2008.8","doi-asserted-by":"publisher","DOI":"10.1007\/BF02201031"},{"key":"2018112909282087000_39.10.2008.9","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E425"},{"key":"2018112909282087000_39.10.2008.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.024026"},{"key":"2018112909282087000_39.10.2008.11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050473"},{"key":"2018112909282087000_39.10.2008.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.21061"},{"key":"2018112909282087000_39.10.2008.13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20319"},{"key":"2018112909282087000_39.10.2008.14","first-page":"424","article-title":"Preliminary criteria for classification of adult Still\u2019s disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"2018112909282087000_39.10.2008.15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00296-011-2096-3","article-title":"Injection-site reactions upon Kineret (anakinra) administration \u2014 Experiences and explanations","volume":"32","author":"Kaiser","year":"2011","journal-title":"Rheumatol Int"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.111549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:18:01Z","timestamp":1543497481000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.111549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2012,10,1]]},"published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.3899\/jrheum.111549"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.111549","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717954643.793491947","asserted-by":"object"}]},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,1]]}}}